All In Biotech

Drug Trial Radar · NCT00448539

Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

An Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Last checked: Nov 19, 2026Latest source record: Nov 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

286

Actual

Start

Mar 15, 2007

Primary completion

May 14, 2010

Study completion May 14, 2010

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Mar 19, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was an open-label extension study in adolescent and adult (between 12 and 80 years old) participants who had completed their participation in Study E2080-A001-301. The main objective of this study was to evaluate the safety and efficacy of long-term administration of rufinamide for the control of epileptic seizures in participants who had refractory partial seizures despite treatment with a maximum of three approved antiepileptic drugs (AEDs).

Conditions

  • Refractory Partial Onset Seizures

Interventions

  • RufinamideDrug

    Dose will be maintained within the range of 2400 to 4800 mg/day (i.e., 1200 to 2400 mg twice daily).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Change in Total Partial Seizure Frequency Per 28 Days Relative to the Baseline PhaseTime frame: Baseline, Titration Phase (Days 1 to 18), Maintenance Phase

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • University of South Alabama Medical Center

    Mobile, Alabama

  • Clinical Trials, Inc.

    Little Rock, Arkansas

  • Bradenton Research Center

    Bradenton, Florida

  • University of Florida, The Neuroscience Institute at Shands

    Jacksonville, Florida

  • Pediatric Neurologists of Palm Beach

    Loxahatchee Groves, Florida

  • Pediatric Neurosciences, PA

    Orlando, Florida

  • Bay Medical Center

    Panama City, Florida

  • Child Neurology Associates, PC

    Atlanta, Georgia

  • Southern Illinois University Neurology and Pharmacology

    Springfield, Illinois

  • McFarland Clinic PC

    Ames, Iowa

  • John Hopkins Hospital, Dept. of Neurology

    Baltimore, Maryland

  • Hattiesburg Clinic

    Hattiesburg, Mississippi

  • Comprehensive Epilepsy Care Center for Children and Adults

    Chesterfield, Missouri

  • Dartmouth Medical School Neuroscience Center

    Lebanon, New Hampshire

  • Five Towns Neuroscience Research

    Cedarhurst, New York

  • New York University Medical Centre, Comprehensive Epilepsy Center

    New York, New York

  • Weill Cornell Medical Center, Comprehensive Epilepsy Center

    New York, New York

  • Asheville Neurology Specialists

    Asheville, North Carolina

  • Ohio State University

    Columbus, Ohio

  • Medical University of Ohio at Toledo - Dept. of Neurology

    Toledo, Ohio

  • Hospital of The University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Pennsylvania Medical Center-Department of Neurology

    Philadelphia, Pennsylvania

  • University of Tennessee Health Sciences Center, Dept. of Neurology

    Memphis, Tennessee

  • Access Clinical Trials, Inc

    Nashville, Tennessee

  • Neurological Clinic of Texas, P.A.

    Dallas, Texas

  • Texas Tech University Health Sciences Center, Dept. of Neuropsychiatry

    El Paso, Texas

  • Fletcher Allen Healthcare

    Burlington, Vermont

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.